Biotechnology firm Retrogenix, which has operations in the UK and US, has appointed Matthew Britz as North American Business Development Director.
Operating out of Retrogenix’s offices in Cambridge, MA, Britz will play a key role in supporting the company’s continued growth in the US and Canada.
Retrogenix’s proprietary cell microarray technology is used by pharmaceutical and biotechnology companies to identify the human cell surface receptors of antibodies, proteins, viruses and small molecules. The high likelihood of finding a molecule’s receptor puts the success rate of the technology around four fold higher than other methods, the company says.
Retrogenix’s expansion in the US follows increased demand for the company's technology, particularly in the area of target deconvolution following phenotypic screening.
Britz, who has recently held business development and strategy consultancy roles within life sciences companies, has held both scientific and managerial positions within several global pharmaceutical companies with a particular focus on biologics research and development.
